A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777) for the treatment of edema associated with congestive heart failure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback